Patient-Specific Decision Making Beyond Guidelines in Advanced Renal Cell Carcinoma

In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline recommendations when multiple appropriate treatment options are available. Dr. Wulff and Dr. Geynisman discuss the importance of individualized decision making, emphasizing that patient-specific factors often guide final treatment selection. Key considerations include performance status, comorbidities, symptom burden, and patient preferences, as well as practical factors such as ability to tolerate immunotherapy or targeted therapy. The panel also highlights the role of disease characteristics, including pace of progression and sites of metastases, in shaping treatment strategy. In addition, they note that toxicity profiles and quality of life considerations are central when choosing between regimens with similar efficacy. The discussion reinforces that while NCCN guidelines provide a strong framework, optimal care in advanced renal cell carcinoma requires tailoring therapy to the unique clinical context of each patient.